Biomarkers of caspofungin resistance in Candida albicans isolates: A proteomic approach. Issue 1 (31st December 2022)

• Record Type: Journal Article
• Authors: De Cesare, Giuseppe Buda; Hafez, Ahmed; Stead, David; Llorens, Carlos; Munro, Carol A.
• Is Part Of: Virulence. Volume 13:Issue 1(2022)
• Page Start: 1005
• Page End: 1018
• Publication Date: 2022-12-31
• Subjects: Candida albicans -- drug resistance -- caspofungin -- proteomics -- interaction network; Virulence (Microbiology) -- Periodicals; Bacterial diseases -- Periodicals; Molecular microbiology -- Periodicals; 579.05
• DOI: 10.1080/21505594.2022.2081291
• Languages: English
• ISSNs: 2150-5608

Abstract

ABSTRACT: Candida albicans is a clinically important polymorphic fungal pathogen that causes life-threatening invasive infections in immunocompromised patients. Antifungal therapy failure is a substantial clinical problem, due to the emergence of an increasing number of drug-resistant isolates. Caspofungin is a common antifungal drug, often used as first-line therapy that inhibits cell wall β-(1, 3)-glucan synthesis. In this work, the cell surface of different echinocandin-resistant C. albicans clinical isolates was compared with sensitive isolates and their responses to echinocandin treatment analyzed. Proteomic analysis detected changes in the repertoire of proteins involved in cell wall organization and maintenance, in drug-resistant strains compared to susceptible isolates and after incubation with caspofungin. Moreover, an interaction network was created from the differential expression results. Our findings suggest drug resistance may involve not only a different cell wall architecture, but also a different response to drugs.